Session

How to manage recurrence after radical prostatectomy

Poster Session 35

  • Location:
    Room 14b (ICM, Level 1)
  • Chairs:
     A. Bossi, Villejuif (FR)
     A.S. Merseburger, Lübeck (DE)
     R. Sood, New Delhi (IN)
  • Aims and objectives of this session

    PSA recurrence after curative treatments is a common problem. During this session we will discuss the patient profile in this situation and 2 adjuvant or salvage modalities with either radiation or PSMA radio guided surgery.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 430
Patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with PSA persistence after radical prostatectomy

By: Gandaglia G.1, Fossati N.2, Dell’Oglio P.2, Damiano R.3, Bianchi M.3, Picozzi M.2, Farina E.2, Cucchiara V.2, Bertini R.2, Dehò F.2, Montorsi F.2, Briganti A.2

Institutes: 1Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy

* 431
External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy

By: Dell’Oglio P.1, Suardi N.1, Boorjian S.2, Fossati N.1, Gandaglia G.1, Tian Z.3, Moschini M.1, Capitanio U.1, Karakiewicz P.3, Montorsi F.1, Karnes J.2, Briganti A.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

432
A novel model to estimate a patient's individual risk of biochemical recurrence after radical prostatectomy

By: Røder M.A.1, Berg K.D.1, Thomsen F.B.1, Kurbegovic S.1, Rytgaard H.C.2, Gruschy L.1, Brasso K.1, Gerds T.A.2, Iversen P.1

Institutes: 1Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen, Denmark, 2University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark

433
Long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy

By: Vilaseca Cabo A.1, Nguyen D.1, Tin A.2, Corradi R.1, Martin-Malburet A.1, Sandhu J.1, Leddy L.1, Sjoberg D.2, Eastham J.1, Scardino P.1, Touijer K.1

Institutes: 1Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

434
Early or delayed radiotherapy in high risk prostate cancer patients treated with radical prostatectomy? Long term results of a multicenter prospective study

By: Maurizi F.1, Antognoni P.2, Bonetta A.3, Bonetto E.M.4, Bortolus R.5, Colombo A.6, Frezza G.7, Gabriele P.8, Giacobazzi P.9, Marcenaro M.10, Mattana F.11, Moro G.12, Rocchi M.B.L.13, Signor M.14, Malinverni G.15

Institutes: 1Az. Osp. Ospedali Riuniti Marche Nord, Dept. of Radiotherapy, Pesaro, Italy, 2Ospedale Di Circolo E Fondazione Macchi, Dept. of Radiotherapy, Varese, Italy, 3Istituti Ospitalieri Di Cremona, Dept. of Radiotherapy, Cremona, Italy, 4Azienda Ospedaliera San Gerardo, Dept. of Radiotherapy, Monza, Italy, 5Centro Di Riferimento Oncologico, Dept. of Radiotherapy, Pesaro, Italy, 6Ospedale “Alessandro Manzoni”, Dept. of Radiotherapy, Lecco, Italy, 7Ospedale Bellaria, Dept. of Radiotherapy, Bologna, Italy, 8IRCCS, Dept. of Radiotherapy, Candiolo, Italy, 9Policlinico Di Modena, Dept. of Radiotherapy, Modena, Italy, 10Istituto Nazionale Per La Ricerca Sul Cancro, Dept. of Radiotherapy, Genova, Italy, 11Policlinico Di Monza, Dept. of Radiotherapy, Monza, Italy, 12Ospedale Degli Infermi ASL BI, Dept. of Radiotherapy, Biella, Italy, 13Università Degli Studi Di Urbino Carlo Bo, Dept. of Biomolecular Science, Urbino, Italy, 14Azienda Ospedaliero Universitaria S. Maria Della Misericordia, Dept. of Radiotherapy, Udine, Italy, 15Az. Osped. “Ordine Mauriziano”, Dept. of Radiotherapy, Turin, Italy

435
Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk

By: Ross A.1, Den R.2, Yousefi K.3, Trock B.1, Davicioni E.4, Tosoian J.1, Thompson D.5, Choeurng V.3, Haddad Z.3, Tran P.6, Trabulsi E.7, Gomella L.8, Lallas C.8, Abdollah F.9, Feng F.10, Dicker A.2, Freedland S.11, Karnes J.12, Schaeffer E.1

Institutes: 1Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, 2Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, 3GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, 4GenomeDx Biosciences, Dept. of Research and Development, Vancouver, Canada, 5Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, 6Johns Hopkins Hospital, Dept. of Radiation Oncology, Baltimore, United States of America, 7Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Epidemiology, Oncology, Environmental Health, Philadelphia, United States of America, 8Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America, 9Henry Ford Hospital, Dept. of Vattikuti Urology Institute, Detroit, United States of America, 10University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America, 11Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, 12Mayo Clinic, Dept. of Urology, Rochester, United States of America

436
The time elapsed between radical prostatectomy and postoperative radiotherapy has a significant impact on the subsequent recovery of erectile function

By: Gandaglia G.1, Fossati N.2, Bianchi M.3, Picozzi M.2, Farina E.2, Cucchiara V.2, Larcher A.2, Karakiewicz P.4, Mirone V.5, Cozzarini C.6, Montorsi F.2, Briganti A.2

Institutes: 1Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 4University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 5University Federico II, Dept. of Urology, Naples, Italy, 6IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy

437
Detrimental role of pre-prostatectomy neoadjuvant androgen deprivation in node-negative patients treated with adjuvant RT

By: Cozzarini C.1, Noris Chiorda B.1, Deantoni C.1, Briganti A.2, Fiorino C.3, Gandaglia G.2, Fossati N.2, Freschi M.4, Sini C.3, Montironi R.5, Montorsi F.2, Di Muzio N.1

Institutes: 1San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Department of Urology, Milan, Italy, 3San Raffaele Scientific Institute, Department of Medical Physics, Milan, Italy, 4San Raffaele Scientific Institute, Department of Pathology, Milan, Italy, 5Polytechnic University of The Marche Region, School of Medicine, AOU Ospedali Riuniti, Department of Pathology, Ancona, Italy

* 438
PSMA-radioguided surgery for recurrent prostate cancer – mid-term follow-up and novel developments

By: Maurer T.1, Eiber M.3, Wirtz M.2, Robu S.2, Schottelius M.2, Rauscher I.3, Schwaiger M.3, Gschwend J.1, Wester H.-J.2

Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, 3Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany

439
When is tumour volume an exclusion criteria for focal therapy? Results from a radical prostatectomy series

By: Fossati N., Gandaglia G., Suardi N., Capitanio U., Zaffuto E., Cucchiara V., Larcher A., Stabile A., Farina E., Salonia A., Montorsi F., Briganti A.

Institutes: IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy

440
Expression of steroid hormone receptors in residual cancer and stromal cells after neoadjuvant chemohormonal therapy with docetaxal for high-risk localized prostate cancer

By: Narita N.1, Nara T.1, Huang M.1, Numakura K.1, Tsuruta H.1, Maeno A.1, Saito M.1, Inoue T.1, Nanjo H.3, Satoh S.2, Habuchi T.1

Institutes: 1Akita University School of Medicine, Dept. of Urology, Aktia, Japan, 2Akita University Hospital, Enter For Kidney Disease and Transplantation, Aktia, Japan, 3Akita University Hospital, Dept. of Pathology, Aktia, Japan

441
Neutrophil‑to‑lymphocyte ratio is associated with survival after radical prostatectomy in prostate cancer

By: Jang W.S.1, Kang Y.J.1, Han J.H.1, Lee J.Y.1, Cho K.S.1, Ham W.S.1, Oh C.K.4, Kim Y.S.2, Lee J.S.3, Cho I.R.4, Choi Y.D.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, 3Cheil General Hospital & Women’s Healthcare Center, Dept. of Urology, Seoul, South Korea, 4Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea

Summary and context
 A.S. Merseburger, Lübeck (DE)